Jun 10, 2024, 16:19
Albert Grinshpun: Combining chemo with SERD in TP53wt ESR1mut breast cancers
Albert Grinshpun, Goldfarb Advanced Breast Cancer Fellow at the Breast Oncology Center of Dana-Farber Cancer Institute, shared a post on X:
“Finally out! We show that combining chemo with SERD is additive, especially in TP53wt ESR1mut breast cancers. The tx paradigm of ER+ MBC should be reconsidered; perhaps we should keep the anti-ER along the way similar to anti-HER2 tx in HER2+ MBC.”
Read further.
Source: Albert Grinshpun/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 14:05
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10